Showing results (321-330 of 378) with videos related to
Sort By:
Pageof 38
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.Human Molecular Genetics|July 17, 2010
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortiumFederico Canzian, David G Cox, V Wendy Setiawan, et al.Human Mutation|May 22, 2019
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestryTara M Friebel, Irene L Andrulis, Judith Balmaña, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.JAMA Oncology|May 27, 2016
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United StatesPaige Maas, Myrto Barrdahl, Amit D Joshi, et al.Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.Nature Medicine|September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialKatia Khoury, Jane L Meisel, Christina Yau, et al.Pageof 38